Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports;Inefficacité de la clozapine en rapport avec un métabolisme augmenté et intérêt de la fluvoxamine : à propos de quatre cas

Encephale

Volumn 33, Issue 5, 2007, Pages 811-818

  Papetti, F ^a   Morel Pingault, V ^a   Buisse, V ^a   Maziere, L ^a   Banayan, M ^a   Thauby, S ^a   Besnard, T ^a   Darcourt, G ^a   Pringuey, D ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

Caffeine; Clozapine; CYT P450 1A2; Fluvoxamine; Treatment resistant schizophrenia

Indexed keywords

CAFFEINE; CLOZAPINE; CYTOCHROME P450 1A2; FLUVOXAMINE; LITHIUM; CYTOCHROME P450; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CASE REPORT; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG OXIDATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIVIDUALIZATION; LOW DRUG DOSE; MANIA; SCHIZOPHRENIA; SMOKING; BRAIN; MALE; METABOLISM; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; CYTOCHROME P-450 ENZYME SYSTEM; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 42449097250     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2007.01.005     Document Type: Article

References (28)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders IV-R, traduction française 2004 Masson Paris
2. R. Bell A. McLaren J. Galanos The clinical use of plasma clozapine levels Aust N Z J Psychiatry 32 4 1998 567 574
3. S. Bender C.B. Eap Very high cytochrome P4501A2 activity and nonresponse to clozapine Arch Gen Psychiatry 55 11 1998 1048 1050
4. S.A. Chong C.H. Tan H.S. Lee Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports J Clin Psychopharmacol 17 1997 68 69
5. G.W. Dalack D.J. Healy J.H. Meador-Woodruff Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings Am J Psychiatry 155 11 1998 1490 1501
6. C.B. Eap S. Bender S.E. Jaquenoud Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene J Clin Psychopharmacol 24 2 2004 214 219
7. M. Fabrazzo S. La Pia P. Monteleone Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia Neuropsychopharmacology 27 6 2002 1050 1055
8. J.M. Kane Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview Br J Psychiatry Suppl 160 1992 41 45
9. J. Kane G. Honigfeld J. Singer Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch Gen Psychiatry 45 9 1988 789 796
10. J.M. Kane G. Honigfeld J. Singer Clozapine in treatment-resistant schizophrenics Psychopharmacol Bull 24 1 1988 62 67
11. J.M. Kane S. Leucht D. Carpenter Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary J Clin Psychiatry 64 Suppl 12 2003 5 19
12. F.J. Kuo H.Y. Lane W.H. Chang Extrapyramidal symptoms following addition of fluvoxamine to clozapine [letter] J Clin Psychopharmacol 18 1998 483 484
13. M.L. Lu H.Y. Lane K.P. Chen Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients J Clin Psychiatry 61 8 2000 594 599
14. M.L. Lu H.Y. Lane S.K. Lin Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances J Clin Psychiatry 65 6 2004 766 771
15. S. Marder D. Wirshing The American Psychiatric Publishing Textbook of Psychopharmacology third ed. 2003 A. Schatzberg and C. Nemeroff Washington 445
16. J.M. Meyer Individual changes in clozapine levels after smoking cessation: results and a predictive model J Clin Psychopharmacol 21 6 2001 569 574
17. D.D. Miller The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia Ann Clin Psychiatry 8 2 1996 99 109
18. O.V. Olesen K. Linnet Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism J Clin Psychopharmacol 20 1 2000 35 42
19. V. Ozdemir W. Kalow A.B. Okey Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine J Clin Psychopharmacol 21 6 2001 603 607
20. V. Ozdemir W. Kalow P. Posner CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia J Clin Psychopharmacol 21 4 2001 398 407
21. ® combination Schizophr Res 79 2–3 2005 345 346 Epub 2005 Aug 25
22. C. Sachse J. Brockmoller S. Bauer Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine Br J Clin Pharmacol 47 4 1999 445 449
23. P. Schulte What is an adequate trial with clozapine? therapeutic drug monitoring and time to response in treatment-refractory schizophrenia Clin Pharmacokinet 42 7 2003 607 618
24. A. Szegedi I. Anghelescu J. Wiesner Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial Pharmacopsychiatry 32 4 1999 148 153
25. J. Van der Weide L.S. Steijns M.J. van Weelden The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement Pharmacogenetics 13 3 2003 169 172
26. L.L. Von Moltke D.J. Greenblatt S.X. Duan Phenacetin O-demethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine Psychopharmacology 128 1996 398 407
27. J.O. Wong S.P. Leung T. Mak Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients Prog Neuropsychopharmacol Biol Psychiatry 30 2 2006 251 264 Epub 2005 Nov 28
28. T. Yokoi M. Sawada T. Kamataki Polyphormic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations Pharmacogenetics 5 1995 S65 S69